Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Case 38% Improvement Relative Risk c19hcq.org Sukumar et al. HCQ for COVID-19 PrEP Favors HCQ Favors control
The Frontline War: A Case-control study of risk factors for COVID-19 among health care workers
Sukumar et al., F1000Research, doi:10.12688/f1000research.109023.1
14 Nov 2022    Source   PDF   Share   Tweet
Case control study of healthcare workers in India, showing lower risk of cases with HCQ prophylaxis, without statistical significance.
While authors comment negatively, as may be required for publication, and this study alone is not statistically significant, the result is consistent with the positive results in all studies to date. Currently there are 86 HCQ for COVID-19 pre-exposure prophylaxis studies, showing 31% lower mortality [11‑46%] and 32% fewer cases [23‑40%].
risk of case, 37.6% lower, OR 0.62, p = 0.30, treatment 10 of 57 (17.5%) cases, 15 of 59 (25.4%) controls, NNT 8.6, case control OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sukumar et al., 14 Nov 2022, retrospective, India, peer-reviewed, survey, 5 authors, study period July 2020 - September 2020.
Contact: vsagar33@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit